Lipum AB (OSTO:LIPUM) FCF Yield % : -9.84 (As of May. 24, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lipum AB FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Lipum AB's Trailing 12-Month Free Cash Flow is kr-13.37 Mil, and Market Cap is kr135.76 Mil. Therefore, Lipum AB's FCF Yield % for today is -9.84%.

The historical rank and industry rank for Lipum AB's FCF Yield % or its related term are showing as below:

OSTO:LIPUM' s FCF Yield % Range Over the Past 10 Years
Min: -71.57 Med: 0 Max: 0
Current: -9.84

OSTO:LIPUM's FCF Yield % is ranked better than
58.37% of 1554 companies
in the Biotechnology industry
Industry Median: -14.35 vs OSTO:LIPUM: -9.84

Lipum AB's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Lipum AB FCF Yield % Historical Data

The historical data trend for Lipum AB's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB FCF Yield % Chart

Lipum AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-36.69

-49.14

-59.79

Lipum AB Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial										-47.97	-55.20	-25.90	-	-48.05

Competitive Comparison of Lipum AB's FCF Yield %

For the Biotechnology subindustry, Lipum AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipum AB's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipum AB's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Lipum AB's FCF Yield % falls into.

Lipum AB FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Lipum AB's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-36.314	/	60.7316980716
	=	-59.79%

Lipum AB's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-7.295	*	4	/	60.7316980716
	=	-48.05%

Lipum AB FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Lipum AB FCF Yield % Related Terms

Thank you for viewing the detailed overview of Lipum AB's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipum AB (OSTO:LIPUM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tvistevagen 48 C, Umea, SWE, 907 36

Website

https://www.lipum.se

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB (OSTO:LIPUM) Headlines

No Headlines